SOURCE: IBC Life Sciences

IBC Life Sciences

March 04, 2009 09:00 ET

TIDES Oligonucleotide and Peptide® Technology and Product Development

May 17-20, 2009 -- Red Rock Casino, Resort & Spa -- Las Vegas, NV

WESTBOROUGH, MA--(Marketwire - March 4, 2009) - IBC's TIDES Oligonucleotide and Peptide® Technology and Product Development will take place May 17-20, 2009 in Las Vegas, NV at the Red Rock Casino, Resort & Spa. This conference is a place for information on manufacturing technologies and drug development, as well as networking and business development in the field of oligonucleotide and peptide-based therapeutics and diagnostics.

The programming features new technologies, formulation and delivery regulatory updates, and courses on quality assurance, manufacturing RNA, bioanalytical techniques, managing analytical development and QC. In addition, attendees will hear case studies from Lilly, Avecia OligoMedicines, OncoGenex, Ipsen, Millennium and Pfizer along with technical and regulatory strategies from Merck, Bristol-Myers, U. of Washington, Regado, Alnylam and Isis.

Keynote Presentations include:

Not Just a Message: Noncoding RNAs in Biology and Medicine
Thomas R. Cech, Ph.D., Distinguished Professor, University of Colorado-
Boulder; Nobel Laureate, 1989 (Chemistry)

Human Genetics and Oligonucleotides: Essential Partners in Pharma's Future
Arthur M. Krieg, M.D., Chief Scientific Officer, Research Technology
Center, Pfizer Inc

Therapeutic Strategies Using RNA Interference
John J. Rossi, Ph.D, Lidow Family Research Chair, Professor, Division of
Molecular Biology; Dean, Graduate School of Biological Sciences; Beckman
Research Institute of City of Hope

Peptide Therapeutics: Trends in Global Clinical Development and Approval
Janice M. Reichert, Ph.D., Senior Research Fellow, Tufts Center for the
Study of Drug Development; Editor-in-Chief, mAbs, Landes Bioscience

Taking Advantage of Peptide Aggregation
Joel P. Schneider, Ph.D., Associate Professor, Department of Chemistry and
Biochemistry, Department of Materials Science and Engineering, University
of Delaware

This forum focuses on development, manufacturing, business and regulatory challenges of oligonucleotide- and peptide-based therapeutics and diagnostics. It consists of 25 scientific sessions with over 80 presentations covering the current technology and market landscape to help attendees plan for future industry trends and meet people in the oligonucleotide and peptide drug development and manufacturing, as well as raw material and equipment supply, fields.

Registration for this event also gives attendees access to the co-located event "Applications of Nucleic Acids Technologies in Molecular Diagnostics."

For more information and to register for this conference please visit,

Contact Information

  • Contact:
    Steve Garofalo
    IBC Life Sciences
    Email Contact